TODAY'S HEADLINES

First 'artificial pancreas' for diabetes approved, plus 2 more FDA actions

The first device to automatically monitor blood sugar and provide appropriate basal insulin doses for patients was recently approved by FDA, along with two new drugs. Read more

Cystic fibrosis drug approved for younger patients

FDA recently expanded the use of lumacaftor/ivacaftor (Orkambi) to treat cystic fibrosis in children aged 6 to 11 years who have two copies of the F508del mutation. Read more

CONTINUING PHARMACY EDUCATION

The role of the community pharmacy team in assisting patients receiving oral anticancer medications

This month's CE activity, "The role of the community pharmacy team in assisting patients receiving oral anticancer medications," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about oral anticancer medications.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Cheaper generic EpiPen doesn't quiet critics

Despite offering a generic version of its EpiPen, Mylan has been unable to curb the backlash that began in late August over the cost of its epinephrine injection. Find out why

October 05, 2016

Related Articles

Invokamet extended-release approved for diabetes

New cystic fibrosis drugs may significantly increase pharmacy benefit costs